11th Annual Udall Centers Directors' Meeting

Udall Center Directors, investigators and invited guests are welcome to attend the 11th Annual Meeting of the Morris K. Udall Centers of Excellence for Parkinson's Disease Research.

The Udall Centers program was established in 1997 immediately following the passage of the Morris K. Udall Parkinson's Disease Research Act into law. There are currently 13 Udall Centers of Excellence across the United States, as well as the associated Parkinson's Disease Data and Organizing Center (PD-DOC) at the University of Rochester. These Centers represent a key component of the NINDS research portfolio in Parkinson's disease and related neurodegenerative disorders.

Since 2007, the site of the annual Centers Director meetings has alternated among existing Udall Centers. This year's meeting will be hosted by Dr. James Bennett, Director of the Udall Center at the University of Virginia. The meeting is designed to provide an optimal environment in which participants can discuss emergent issues in the research and treatment of Parkinson's disease. The Agenda will include updates on recent advances in the Centers and a focused scientific session related to timely issues in Parkinson's disease research and treatment, as well-discussion sessions on cross-cutting topics and poster presentations designed to maximize interactions among participants. By providing a focused and interactive Agenda, the annual meeting fosters the initiation and maintenance of collaborative efforts among the Centers.

Agenda and Speakers (NINDS)

NINDS Udall Center Updates

Hot Topics@Udall 2009

Hot Topics@Udall 2009
06 Oct 2009
I whole-heartedly agree that brain-banking for PD is not what it should be. First and foremost, this is due to underfunding.  Most brain banks are really subsidized heavily by the fact that the ... 
Hot Topics@Udall 2009
24 Sep 2009
The scientific session of the 11th Annual Morris Udall Parkinson’s Center Conference had four speakers.  ... 
Hot Topics@Udall 2009
22 Sep 2009
Dr. James Bennett began this morning's discussion speaking about the translational "Valley of Death", that time between pre-IND research to the end of Phase 1 trials when most clinical therapeutic ...